A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Key Inclusion Criteria:

• At least 18 years of age.

• Histologically confirmed unresectable or metastatic melanoma.

• Subject has no prior systemic treatment for advanced disease.

• Subject must have measurable disease according to Response Evaluation Criteria inSolid Tumors (RECIST version 1.1).

• Tumor tissue from site of unresectable or metastatic melanoma must be available forbiomarker analyses in order to be randomized.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

Key Exclusion Criteria:

• Subject has had any prior systemic anti-cancer therapy for the treatment of advancedmelanoma.

• Known hypersensitivity to monoclonal antibodies or to any of the excipients of thestudy drug.

• Subject has active central nervous system (CNS) metastases not previously treated.

• Ocular melanoma.

• Subject has active or known immune-mediated disorders.

• Subject has had prior treatment with PD-1/PD-L1 and cytotoxic T lymphocyte-associated protein 4 inhibitors, or other antibodies targeting immune checkpointpathways.

• Subject has medical conditions requiring systemic immunosuppression with eithercorticosteroids or other immunosuppressive medications within 14 days of the firstdose of investigational product.

Other protocol-defined inclusion/exclusion criteria apply.